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Abstract
Background: Rhipicephalus sanguineus is the most widely distributed tick species infesting dogs worldwide, which
may cause discomfort to the host and transmit diseases. Acaricides with a rapid and sustained speed of kill are thus
important to prevent infestation and to reduce the risk of disease transmission. In this study, the speed of kill of a
monthly administered SimparicaTM(sarolaner) treatment against induced infestations with R. sanguineus on dogs
was evaluated and compared with a single dose of Bravecto®(fluralaner) for 95 days after the initial treatment.
Methods: Twenty four dogs were randomly allocated to treatment and were treated with either placebo or sarolaner
(at 2 to 4 mg/kg) on Days 0, 30 and 60 or with fluralaner (at 25 to 56 mg/kg) once on Day 0. Tick counts were
performed in situ 8 and 12 h and with removal of the ticks 24 h after treatment and subsequent re-infestations on
Days 14, 28, 44, 56, 74, 90 and 95. Acaricidal efficacy was determined at each time point relative to the placebo group.
Results: Both products significantly reduced live ticks within 8 h after treatment against an existing infestation with R.
sanguineus, and killed all ticks on all dogs within 24 h. After re-infestation, sarolaner provided ≥98.5 % reduction within
24 h on all days except Days 74 and 95 (P < 0.0001), compared to fluralaner which provided ≥95.5 % reduction until
Day 44. Geometric mean live tick counts for sarolaner were significantly lower (P≤ 0.0415) at 24 h than those for
fluralaner on all days, except on Days 0, 14 and 28 (P≥ 0.0678). There were no treatment-related adverse reactions
observed during the study.
Conclusions: When dosed at monthly intervals for 3 consecutive months, SimparicaTM has a faster and more consistent
speed of kill against R. sanguineus than a single oral dose of Bravecto® for which efficacy decreased after Day 44.
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Background
Rhipicephalus sanguineus, also known as the kennel tick
or brown dog tick, has a worldwide distribution in areas
with a relatively warm climate and mild winters [1, 2].
The introduction of R. sanguineus in regions with less
favorable conditions has been described, mainly through
dogs returning from travel in endemic areas [3–7]. As
the tick is known to complete the life cycle in-house and
as climate and environmental conditions become more
suitable [7, 8], expansion to new distribution areas is an-
ticipated. Rhipicephalus sanguineus is prevalent both in
rural and urban areas [1, 9], and is a known vector for
several vector-borne pathogens, including Ehrlichia spp.,
Babesia canis, Hepatozoon canis and several Rickettsia
spp. [1, 10]. The awareness of and exposure to tick-
borne diseases increases and has driven the emphasis on
tick control and prevention in recent years. Simpari-
caTM(sarolaner) is an oral isoxazoline parasiticide that
provides excellent treatment and prevention of ticks, in-
cluding R. sanguineus, for at least 5 weeks after a single oral
dose [11]. Although the systemically active compounds re-
quire the tick to bite to be effective, the isoxazolines are
known to act rapidly. A single dose of sarolaner provides
adequate efficacy against Ixodes ricinus, I. scapularis,
Dermacentor reticulatus and Amblyomma maculatum
within 24 h after treatment or re-infestation for at least
4 weeks [12, 13]. The present study aimed to evaluate and
compare the speed of kill of a monthly oral dose of sarola-
ner with a single oral dose of Bravecto® (fluralaner) against
an existing infestation and against re-infestations with R.
sanguineus for a period of 95 days.
Methods
Ethical approval
Study procedures were in accordance with the World
Association for the Advancement of Veterinary Parasit-
ology (WAAVP) guidelines for evaluating the efficacy of
parasiticides for the treatment, prevention and control
of flea and tick infestation on dogs and cats [14]. The
protocol was reviewed and approved by the Zoetis Ethical
Review Board and local Animal Welfare Committee.
Masking of the study was assured through the separation
of study functions. All personnel conducting observations
or animal care or performing infestations and counts were
masked to treatment allocation.
Animals
Twenty-four (12 male and 12 female) purpose-bred Beagle
and mixed breed dogs from 11 months to 9 years of age
and weighing from 9.4 to 22.8 kg were used in the study.
Each dog had undergone an adequate wash-out period to
ensure that no residual ectoparasiticide efficacy remained
from any previous treatment. Dogs were individually
housed and they were acclimatized to these conditions for
8 days prior to treatment. Dogs were fed an appropriate
maintenance ration of a commercial canine feed for the
duration of the study. Water was available ad libitum. All
dogs were given a physical examination to ensure that
they were in good health at enrollment and were suitable
for inclusion in the study. General health observations
were performed twice daily throughout the study.
Design
The study followed a randomized complete block design.
Dogs were ranked according to decreasing pre-treatment
tick counts (48 h after infestation on Day-7) into blocks of
three animals, and within each block a dog was randomly
allocated to one of three treatment groups. There were
eight dogs per treatment group.
Treatment
On Days 0, 30 and 60, two groups of dogs each received
either a placebo tablet or an appropriate SimparicaTM
chewable tablet to provide label dose (sarolaner at 2 to
4 mg/kg). The third group of dogs received a Bravecto®
tablet (per label providing fluralaner at 25 to 56 mg/kg)
on Day 0 and placebo tablets on Days 30 and 60. In order
to comply with the Bravecto® label requirement, all dogs
were fed within 20 min of the treatment administration.
The tablet(s) were administered by hand pilling to ensure
accurate and complete dosing. Each dog was observed for
several minutes after dosing for evidence that the dose
was swallowed, and for potential adverse events associated
with treatment administration. Dogs were observed ap-
proximately two hours after dosing for evidence of emesis.
Tick infestation and assessment
The R. sanguineus strain used for infestation was origin-
ally isolated from the field in France in 2007. The colony
was genetically enriched by the addition of wild-caught
ticks from France in 2012. For treatment allocation dogs
were infested with ticks on Day -7 and ticks counts were
conducted 48 h later. Further tick infestations were per-
formed on Days -2, 14, 28, 42, 56, 74, 90 and 95. Prior
to each infestation, the dog was sedated to enhance tick
attachment, and 50 (±5) viable unfed adult R. sanguineus
(1:1 male:female) were directly applied to each animal.
Tick counts were conducted at 8, 12 and 24 (±0.5) hours
after treatment and each subsequent weekly re-infestation.
Ticks were counted in situ (thumb counts) at the 8 and
12 h time points by systematic examination of the en-
tire body surface to ensure that any area was examined
only once. At the 24 h counts, dogs were examined and
then thoroughly combed to count and remove ticks.
Each dog was examined for at least 10 min. If ticks
were encountered in the last minute, combing was
continued in one minute increments until no ticks
were encountered.
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Statistical analysis
The individual dog was the experimental unit. Data for
post-treatment live (free plus attached) tick counts were
summarized with arithmetic (AM) and geometric (GM)
means by treatment group and timepoint. Tick counts
were transformed by the loge(count + 1) transformation
prior to analysis in order to stabilize the variance and
normalize the data. Using the PROC MIXED procedure
(SAS 9.2, Cary NC), transformed counts were analyzed
using a mixed linear model for repeated measures. The
fixed effects were treatment, time-point and the treat-
ment by time-point interaction. Random effects in-
cluded room, block within room, block by treatment
interaction within room, and error. Testing was two-
sided at the significance level α = 0.05. The assessment
of acaricidal efficacy was based on the percent reduc-
tion in the arithmetic and geometric mean live tick
counts relative to placebo [15], and was calculated
using Abbott’s formula:
% reduction
¼ 100  mean count placeboð Þ– mean count treatedð Þ
mean count placeboð Þ
Results
The results of the tick counts at each time-point are pro-
vided in Tables 1, 2 and 3, and in Fig. 1. Placebo-treated
dogs maintained adequate tick infestations throughout the
study. Both products significantly reduced tick counts
within 8 h after the initial treatment (P < 0.0001) and
achieved >90 % efficacy by 12 h against the existing infest-
ation. At 8 and 12 h after subsequent weekly re-
infestations both products had a variable speed of kill and
efficacy tended to decline towards the end of the treat-
ment period with tick counts for both groups not being
significantly different from placebo on Days 58, 74 and 95
(Tables 1 and 2).
Twenty-four hours after treatment, no live ticks were
found on any sarolaner or fluralaner-treated dog (100 %
efficacy; P < 0.0001 vs placebo; Table 3). Twenty-four
hours after subsequent re-infestations, the reduction in
AM (GM) tick counts for sarolaner was above 98.5 %
(99.0 %) for 4 weeks after each monthly treatment,
except on Day 74 when efficacy was 81.9 % (83.8 %).
GM live tick counts for sarolaner were significantly
lower (P < 0.0001) than placebo on all days. The reduction
in AM (GM) tick counts for fluralaner was ≥95.5 %
(96.9 %) until Day 44, and ranged from 42.2 % (47.9 %) to
87.5 % (93.5 %) for the remainder of the study period. GM
live tick counts for both products were significantly lower
(P≤ 0.0011) than placebo on all days, and significantly
fewer (P≤ 0.0415) live ticks were found on sarolaner-
treated dogs compared to fluralaner-treated dogs from
Day 44 onwards. There were no treatment-related adverse
reactions during the study.
Table 1 Efficacy of sarolaner after three monthly treatments on Days 0, 30 and 60 and after a single oral dose of fluralaner on Day 0
against Rhipicephalus sanguineus on dogs 8 h after treatment and re-infestations (AM: arithmetic mean live tick counts; GM: geometric
mean live counts)
Treatment Day of infestation
0 14 28 44 58 74 90 95
Placebo Range 15 to 34 15 to 38 20 to 39 15 to 37 12 to 30 19 to 36 19 to 28 21 to 41
AM 20.5 23.8 32.3 28.0 24.3 28.8 23.9 31.8
GMd 19.8a 22.8a 31.6a 27.3a 23.3a 28.2a 23.7a 31.3a
Sarolaner Range 0 to 33 11 to 25 9 to 19 9 to 23 11 to 29 17 to 49 8 to 20 21 to 36
AM 6.3 14.5 14.1 14.0 20.0 31.6 12.1 26.8
AM Efficacy (%) 69.5 38.9 56.2 50.0 17.5 0.0 49.2 15.7
GMd 2.7b 14.0b 13.8b 13.5b 19.0a 30.4a 11.7b 26.3a
GM Efficacy (%) 86.6 38.5 56.3 50.6 18.5 0.0 50.8 16.0
P-value vs. placebo <0.0001 0.0126 <0.0001 0.0003 0.2857 0.6949 0.0004 0.3561
Fluralaner Range 0 to 10 9 to 17 6 to 16 9 to 24 14 to 28 21 to 34 5 to 23 21 to 39
AM 2.3 13.3 10.0 16.5 23.0 26.0 13.8 25.4
AM Efficacy (%) 89.0 44.2 69.0 41.1 5.2 9.6 42.4 20.1
GMd 1.3c 13.0b 9.5b 15.7b 22.5a 25.6a 12.8b 24.9a
GM Efficacy (%) 93.6 43.0 69.9 42.4 3.4 9.3 46.1 20.3
P-value vs. placebo <0.0001 0.0050 <0.0001 0.0055 0.8580 0.6132 0.0021 0.2415
P-value vs. sarolaner 0.0433 0.7638 0.1461 0.5413 0.4936 0.4822 0.7219 0.8301
dGeometric means within a counting day with the same superscript are not significantly different (P > 0.05)
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Table 2 Efficacy of sarolaner after three monthly treatments on Days 0, 30 and 60 and after a single oral dose of fluralaner
on Day 0 against Rhipicephalus sanguineus on dogs 12 h after treatment and re-infestations (AM: arithmetic mean live tick counts; GM:
geometric mean live counts)
Treatment Day of infestation
0 14 28 44 58 74 90 95
Placebo Range 11 to 35 17 to 37 20 to 39 24 to 37 13 to 26 12 to 34 20 to 26 20 to 38
AM 20.8 24.1 31.6 28.3 21.4 26.8 22.3 29.1
GMd 19.7a 23.5a 31.1a 28.0a 20.8a 25.8a 22.2a 28.7a
Sarolaner Range 0 to 11 2 to 12 7 to 14 5 to 14 9 to 23 12 to 38 5 to 22 20 to 33
AM 1.6 8.0 10.0 10.0 17.0 26.9 12.1 25.5
AM Efficacy (%) 92.2 66.8 68.4 64.6 20.5 0.0 45.5 12.4
GMd 0.6b 7.3b 9.7b 9.6b 16.3a 25.7a 11.1b 25.1a
GM Efficacy (%) 96.8 69.0 68.7 65.7 21.6 0.3 49.8 12.4
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 0.2065 0.9863 0.0005 0.4861
Fluralaner Range 0 to 2 2 to 11 3 to 10 5 to 19 9 to 24 19 to 32 5 to 17 21 to 29
AM 0.4 5.9 5.8 11.0 16.4 24.4 12.8 24.9
AM Efficacy (%) 98.2 75.6 81.8 61.1 23.4 8.9 42.7 14.6
GMd 0.3b 5.3b 5.3c 9.9b 15.4a 23.9a 12.1b 24.7a
GM Efficacy (%) 98.7 77.5 83.1 64.5 26.1 7.3 45.4 13.7
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 0.1267 0.6959 0.0027 0.4485
P-value vs. sarolaner 0.2720 0.2450 0.0238 0.8946 0.8149 0.7673 0.7431 0.9509
dGeometric means within a counting day with the same superscript are not significantly different (P > 0.05)
Table 3 Efficacy of sarolaner after three monthly treatments on Days 0, 30 and 60 and after a single oral dose of fluralaner
on Day 0 against Rhipicephalus sanguineus on dogs 24 h after treatment and re-infestations (AM: arithmetic mean live tick
counts; GM: geometric mean live counts)
Treatment Day of infestation
0 14 28 44 58 74 90 95
Placebo Range 14 to 36 21 to 39 21 to 39 21 to 37 14 to 29 18 to 36 22 to 31 25 to 37
AM 23.5 26.3 28.8 28.0 25.0 29.0 25.8 30.5
GMd 22.8a 25.8a 28.2a 27.6a 24.4a 28.3a 25.6a 30.2a
Sarolaner Range 0 to 0 0 to 1 0 to 1 0 to 2 0 to 1 1 to 11 0 to 2 0 to 11
AM 0.0 0.3 0.1 0.3 0.3 5.3 0.4 3.8
AM Efficacy (%) 100 99.0 99.6 99.1 99.0 81.9 98.5 87.7
GMd 0.0b 0.2b 0.1b 0.1c 0.2c 4.6c 0.3c 2.5c
GM Efficacy (%) 100 99.3 99.7 99.5 99.2 83.8 99.0 91.9
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Fluralaner Range 0 to 0 0 to 3 0 to 1 0 to 5 0 to 8 4 to 27 4 to 20 2 to 32
AM 0.0 1.1 0.1 1.3 3.1 16.8 10.8 14.8
AM Efficacy (%) 100 95.7 99.6 95.5 87.5 42.2 58.3 51.6
GMd 0.0b 0.8b 0.1b 0.9b 1.6b 14.8b 9.1b 10.8b
GM Efficacy (%) 100 96.8 99.7 96.9 93.5 47.9 64.6 64.3
P-value vs. placebo <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0011 <0.0001 <0.0001
P-value vs. sarolaner 1.0000 0.0678 1.0000 0.0415 0.0012 <0.0001 <0.0001 <0.0001
dGeometric means within a counting day with the same superscript are not significantly different (P > 0.05)
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Discussion
Sarolaner significantly reduced R. sanguineus tick counts
within 8 h after the first treatment on Day 0 and demon-
strated a consistently high efficacy within 24 h after 3
monthly treatments. In contrast, the speed of kill of flur-
alaner was significantly slower from Day 44 onwards.
These results are consistent with a previous study in
which the speed of kill of fluralaner against R. sangui-
neus and Dermacentor reticulatus also decreased in the
third month after treatment [15]. In the present study,
significantly more R. sanguineus ticks were found on the
fluralaner-treated dogs from Day 44 onwards compared
to dogs treated monthly with sarolaner. These results
illustrate that the perceived benefit of a longer treatment
interval and hence the need for less treatments, needs to
be balanced with the potential risk of an unpredictable
decline in efficacy at the end of the claimed treatment
period. An important benefit of monthly sarolaner
administration is that it provides a sustained efficacy
against all relevant tick species in dogs [11] as well as
maintaining a rapid speed of kill for the entire duration
of the efficacy claim period against R. sanguineus and
other tick species (I. ricinus, I. scapularis, D. reticulatus
and A. maculatum) [12, 13]. As R. sanguineus is the
vector of a range of tick-borne diseases worldwide, the
rapid and consistent speed of kill provided by monthly
treatments with sarolaner will be an important aid in the
prevention of tick-borne disease transmission.
Conclusions
This study confirmed the consistent acaricidal efficacy of
sarolaner against R. sanguineus and demonstrated that
ticks were killed rapidly during the entire treatment
period. Monthly treatment with sarolaner consistently
killed more ticks within 24 h than a single dose of flura-
laner from 6 to 13 weeks after initial treatment.
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